David J. Woodhouse - Dec 29, 2021 Form 4 Insider Report for NGM BIOPHARMACEUTICALS INC (NGM)

Role: Chief Executive Officer, Director
Signature: /s/ Valerie Pierce, Attorney-in-fact
Stock symbol: NGM
Transactions as of: Dec 29, 2021
Transactions value $: $137,989
Form type: 4
Date filed: 12/30/2021, 04:09 PM
Previous filing: Nov 19, 2021
Next filing: Mar 4, 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	NGM	Common Stock	Options Exercise	$100K	+13K		$7.70^*	13K	Dec 29, 2021	Direct
transaction	NGM	Common Stock	Options Exercise	$38K	+4.67K	+35.94%	$8.14^*	17.7K	Dec 29, 2021	Direct
holding	NGM	Common Stock						80K	Dec 29, 2021	See footnote	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	NGM	Stock Option (Right to Buy)	Options Exercise	$0	-13K	-12.99%	$0.00	87K	Dec 29, 2021	Common Stock	13K	$7.70	Direct	F2
transaction	NGM	Stock Option (Right to Buy)	Options Exercise	$0	-4.67K	-7.47%	$0.00	57.8K	Dec 29, 2021	Common Stock	4.67K	$8.14	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Shares held by The Woodhouse Family Trust 9/8/05.
F2	Fully vested.
F3	The shares subject to the stock option are early exercisable and vest over a four-year period commencing January 1, 2018, with 1/48th of the shares vesting on a monthly basis.